Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Engaging Medical Play Sees Stock Price Settle

Stockhouse Editorial
3 Comments| September 14, 2021

{{labelSign}}  Favorites
{{errorMessage}}

Click to enlargeClinical-stage biotechnology company N8BIO Inc. (NASDAQ: INAB, Forum) recently reported a net loss of $1.00 (USD) per share for Q2 2021, versus a year-ago loss of $0.92 per share.

INAB shares gained 3% to close at $8.89 on Friday and has fallen 2.9% over the past month.

The company noted that the research and development expense was $2.1 million (USD), compared to $1.8 million for the comparable prior year period. The increase in R&D expense was said to be due primarily to third-party costs associated with our clinical programs for INB-200 and increased personnel costs, including non-cash stock-based compensation.

Currently conducting two investigator-initiated Phase 1 clinical trials, N8bio’s lead gamma-delta T-cell product candidates are INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation.

INB-200 was generally well tolerated with no observed infusion reactions, cytokine release syndrome, neurotoxicity or dose limiting toxicities. IN8bio completed dosing of the first cohort of INB-100, a Phase 1 clinical trial of donor-derived allogeneic gamma-delta T cells in leukemia patients undergoing hematopoietic stem cell transplant in August 2021. The Company expects to report initial results from the first cohort in this Phase 1 trial in 2022, with topline results for all cohorts in 2023.

IN8bio also presented data demonstrating in vitro activity of INB-300, its DeltEx drug-resistant immunotherapy CAR-T cells against glioblastoma multiforme.


New to investing in Health Care? Check out Stockhouse tips on How to Invest in Health Care Stocks and some of our Top Health Care Stocks.

For more of the latest info on Health Care, check out the Health Care Trending News hub on Stockhouse.




{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today